• 14 June 2007
  • News
  • By

Intas BioPharmaceuticals

New Page 1

Intas BioPharmaceuticals

Business: R&D, manufacturing and marketing of biotech products

Biotech Revenue: Rs 7.64 crore

CEO: Dr Urmish Chudgar (MD)

Start-up Year: 2001

Address: Plot No. 423 / P / A/ GIDC, Sarkhej - Bavla Highway, Moraiya 382 210, Taluka – Sanand, Ahmedabad, Gujarat

Tel.: +91-2717 - 660100

Fax: +91- 2717 - 251189

Website: www.intasbiopharma.co.in

Intas BioPharmaceuticals Ltd (IBPL) is one of the fastest growing biopharmaceutical companies in India (CAGR 25 percent). Its sales revenue has increased to Rs 7.64 crore in 2006-07 from the previous year's sales revenue of Rs 5.19 crore with major contribution from GCSF.

IBPL has a 100 percent R&D subsidiary, Indus Biotherapeutics, which has a vibrant and expert team of scientists and technical professionals. The ultra modern R&D facility is well established for microbial and cell culture based upstream processing, downstream processing and protein purity-impurity profile analysis. Its manufacturing facility includes sophisticated and modernized cGMP plant approved to manufacture microbiological and cell culture derived bulk drugs and finished product in pre-filled syringes and vials (lyophilized). It has launched three biogeneric products in the market: Neukine (rHu G-CSF), Erykine and Epofit (rHu EPO) and Intalfa (rHu IFN Alfa-2b). Its R&D team is now working on PEG G-CSF, other cytokines and hormones. IBPL's products in pipeline include recombinant products, monoclonal antibodies, introducing novel technology platforms, molecular biology, novel drug delivery systems, advanced analytical techniques and efficient manufacturing processes.

Currently IBPL is executing contract research and manufacturing agreements with a European client for development, scale-up and commercial supply of a novel biotherapeutic protein.


Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email